Search alternatives:
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
point decrease » point increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
point decrease » point increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
-
2
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). …”
-
3
Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae
Published 2025“…For predicting decreased-susceptibility strains with A501 mutations, MIRCA achieved 98.33% agreement with Sanger sequencing. …”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
11
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
12
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
13
Inotodiol decreases clone formation in HCC cells.
Published 2025“…In addition, inotodiol showed to induce apoptosis, characterized by an increase in Bax expression, a decrease in Bcl-2, Bcl-XL and MCL1 expression, the initiation of cleaved PARP1 and cleaved caspase 3, and inhibition of the MAPK/ERK pathway. …”
-
14
-
15
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
16
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
17
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
18
-
19
B2 decreases glycolytic intermediates in cells.
Published 2025“…<b>(C)</b> Heatmap of targeted metabolomic data. Each column is a separate biological replicate (n = 5). The box indicates the clustering of decreased downstream glycolytic intermediates in B2-treated cells. …”
-
20